Screening hundreds of already approved drugs, researchers discovered a common ingredient in cough syrup called ambroxol increased the activity of GCase. Following this discovery, Parkinson's ...

In a small, open-label, single-center study of Parkinson's patients, ambroxol crossed the blood-brain barrier and boosted β-glucocerebrosidase (GCase) enzyme protein levels, reported Anthony ...

The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has started a safety review of medicines that contain ambroxol and bromhexine. The medicines are used ...

Early studies suggest the drug, called ambroxol, appears to remove damaging proteins from the brain which are associated with the degenerative disease. Currently there are no treatments capable of ...

Medicines containing ambroxol or bromhexine carry a small risk for severe skin reactions, which include erythema multiforme and Stevens-Johnson syndrome, and the product labels should be updated ...